文献速递前列腺癌

胚系DNA损伤修复基因变异对高危局限前列腺癌强化新辅助雄激素剥夺治疗反应的影响

Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
PubMed 文献 · Eur Urol · 2021-04-19

该研究对来自五项随机多中心临床试验的201例中高危局限前列腺癌患者进行胚系基因测序,评估致病性胚系DNA损伤修复(gDDR)基因变异对强化新辅助雄激素剥夺治疗(ADT)后病理反应及生化复发的影响。结果显示gDDR变异患病率为9.5%,最常见为BRCA2和ATM;gDDR变异患者与无变异者的卓越病理反应率、pT3分期、淋巴结受累、包膜外侵犯、切缘阳性率及3年生化复发无生存率均相似。结论认为gDDR变异患者对强化新辅助ADT的反应与无变异者相当,不应被排除在此治疗之外。

要点

  • 中高危局限前列腺癌中致病性gDDR变异患病率为9.5%,BRCA2和ATM最常见。
  • gDDR变异患者与无变异者的卓越病理反应率相似(26% vs 22%)。
  • gDDR变异患者3年生化复发无生存率与无变异者相似(45% vs 55%)。

核心结论

  • gDDR变异在中高危局限前列腺癌中常见,且患者对强化新辅助ADT的反应与无变异者相当,不应被排除在此治疗之外。

研究设计与样本

  • 对来自五项随机多中心临床试验的201例中高危局限前列腺癌患者进行胚系panel测序,这些试验均采用强化新辅助ADT后根治性前列腺切除术。

主要发现

  • 201例患者中19例(9.5%)检测到致病性gDDR变异,最常见为BRCA2(6例,3.0%)和ATM(4例,2.0%)。
  • gDDR变异患者与无变异者的卓越病理反应率分别为26%和22%,pT3疾病分别为42%和53%,淋巴结受累分别为5.3%和10%,包膜外侵犯分别为35%和54%,切缘阳性分别为5.3%和13%(所有p>0.05)。
  • gDDR变异患者3年生化复发无生存率为45%(95%CI 7.9-78%),无变异者为55%(95%CI 44-64%)。

关键数值与推荐

  • 卓越病理反应定义为完全缓解或微小残留病(残留肿瘤最大横截面直径≤5 mm)。
  • 致病性gDDR变异患病率为9.5%(19/201)。
  • BRCA2变异频率为3.0%(6/201),ATM为2.0%(4/201)。

临床怎么用

  • 对于中高危局限前列腺癌患者,gDDR变异状态不应作为排除强化新辅助ADT的依據。
  • gDDR变异患者接受强化新辅助ADT后的病理反应和生化复发结局与无变异者相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intense neoadjuvant androgen deprivation therapy (ADT) before radical prostatectomy (RP) is an investigational approach to reduce recurrence rates in men with high-risk localized prostate cancer (PCa). The impact of germline DNA damage repair (gDDR) gene alterations on response to intense neoadjuvant ADT is not known. OBJECTIVE: To evaluate the prevalence of gDDR alterations among men with localized PCa at high risk of recurrence and evaluate their impact on response to intense neoadjuvant ADT. DESIGN, SETTING, AND PARTICIPANTS: We performed germline panel sequencing for 201 men with intermediate- and high-risk localized PCa from five randomized multicenter clinical trials of intense neoadjuvant ADT before RP. INTERVENTION: Intense neoadjuvant ADT followed by RP. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The prevalence of pathogenic gDDR alterations and their association with exceptional pathologic response (complete response or minimal residual disease, defined as residual tumor with the largest cross-section dimension ≤5 mm) to intense neoadjuvant ADT and rates of post-RP biochemical recurrence. RESULTS AND LIMITATIONS: Pathogenic gDDR alterations were detected in 19 (9.5%) of the 201 PCa patients. The most frequently altered genes were BRCA2 (n = 6; 3.0%) and ATM (n = 4; 2.0%). Patients with gDDR alterations exhibited similar rates of exceptional pathologic response (26% vs 22%), pT3 disease (42% vs 53%), lymph node involvement (5.3% vs 10%), extraprostatic extension (35% vs 54%), and positive margins (5.3% vs 13%) to patients without gDDR alterations (all p > 0.05). The 3-yr biochemical recurrence-free survival was also similar at 45% (95% confidence interval 7.9-78%) for men with gDDR alterations and 55% (95% confidence interval 44-64%) for men without gDDR alterations. CONCLUSIONS: gDDR alterations are common among men with intermediate- and high-risk localized PCa. Men with gDDR alterations appear to have a comparable response to intense neoadjuvant ADT to that among men without gDDR alterations and should not be excluded from consideration for this treatment approach. PATIENT SUMMARY: Intense therapy to inhibit the production of androgen hormones (eg, testosterone) before surgery may minimize the risk of cancer recurrence for men with high-risk localized prostate cancer. Inherited mutations in certain DNA repair genes are associated with particularly high rates of recurrence. We found that men with these mutations respond equally well to this intense androgen inhibition before surgery as men without the mutations.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Berchuck JE, Zhang Z, Silver R, et al. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. Eur Urol. 2021. PMID: 33888356. doi:10.1016/j.eururo.2021.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。